Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 101–200 of 2,053
Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions
Perreault, L., Vincent, L., Neumiller, J. J., & Cavaiola, T. S. (2019) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2019.03.180162 · Cited by 49
Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
Rosenstock, J., Vázquez, L., Del Prato, S., Franco, D. R., Weerakkody, G., Dai, B., Landó, L. F., Bergman, B. K., & Rodríguez, A. (2023) · Diabetes Care · doi:10.2337/dc23-0872 · Cited by 45
Agarwal, R., & Fouque, D. P. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac331 · Cited by 50
Mirjalili, S. R., Soltani, S., Meybodi, Z. H., Marques-Vidal, P. M., Kraemer, A., & Sarebanhassanabadi, M. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01939-9 · Cited by 51
“The first line of diabetes treatment is metformin which can decrease insulin resistance [62], confirming the insignificant association between the TyG-index and CHD in diabetic participants.”
BackgroundAge and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis
Hanlon, P., Butterly, E. W., Wei, L. S., Wightman, H., Almazam, S. A., Alsallumi, K., Crowther, J., McChrystal, R., Rennison, H., Hughes, K., et al. (2025) · JAMA · doi:10.1001/jama.2024.27402 · Cited by 64
“3,18 We aimed to perform a systematic review and meta-analysis of both aggregate and individual participant trial data to estimate whether the efficacy of SGL2i, GLP1ra and DPP4i therapy for type 2 diabetes differs by age and sex.”
Hurtado, I., Robles, C., Peiró, S., García-Sempere, A., & Sanfélix-Gimeno, G. (2024) · Diabetologia · doi:10.1007/s00125-024-06243-z · Cited by 45
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“Due to initial concerns about potential risks in preclinical studies [8], they are not recommended for T2DM patients with diseases such as severe gastrointestinal disease, medullary carcinoma of the thyroid [131], multiple endocrine neoplasm syndrome type 2, and history of pancreatitis [126].”
BackgroundHaguet, Q., Joubioux, F. L., Chavanelle, V., Groult, H., Schoonjans, N., Langhi, C., Michaux, A., Otero, Y. F., Boisseau, N., Peltier, S. L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043652 · Cited by 52
“Incidentally, a reduction in adiposity alone is a strong stimulus for improvement of glucose control [83], which has subsequently made body weight management an integral part of the recommendations of major health organizations worldwide for people with prediabetes or T2D, to improve glucose metabolism [84].”
BackgroundRodriguez‐Valadez, J. M., Tahsin, M., Fleischmann, K. E., Masharani, U. B., Yeboah, J., Park, M., Li, L., Weber, E. S., Li, Y., Berkalieva, A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-0772 · Cited by 49
Efficacy and safety of semaglutide in non-alcoholic fatty liver disease
Zhu, K., Kakkar, R., Chahal, D., Yoshida, E. M., & Hussaini, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i37.5327 · Cited by 62
Sawami, K., Tanaka, A., & Node, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02500-y · Cited by 44
“…risk factors (dyslipidaemia, hypertension, obesity, smoking, etc.) [8, 9], considering "what drugs to use to lower blood glucose" by selecting hypoglycae-mic agents with evidence-based cardiorenal protective effects, according to patient background and risk status is increasingly important [10].”
Patel, H., Khunti, K., Rodbard, H. W., Bajaj, H. S., Bray, R., Kindracki, Z., & Rodríguez, Á. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15333 · Cited by 43
Borel, A.-L., Lablanche, S., Waterlot, C., Joffray, E., Barra, C., Arnol, N., Amougay, H., & Benhamou, P.-Y. (2024) · Diabetes Care · doi:10.2337/dc24-0623 · Cited by 43
Bica, I.-C., Stoica, R. A., Salmen, T., Janež, A., Volčanšek, Š., Popovic, D. S., Muzurović, E. M., Rizzo, M., & Stoian, A. P. (2023) · Medicina · doi:10.3390/medicina59061136 · Cited by 48
“Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are an antidiabetic class with established cardiovascular benefits and promising effects for T2DM and NAFLD/NASH patients [15].”
BackgroundPiccirillo, F., Mastroberardino, S., Nusca, A., Frau, L., Guarino, L., Napoli, N., Ussia, G. P., & Grigioni, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210164 · Cited by 58
“As stated in the latest ADA/EASD guidelines, type-2 DM is a chronic complex disease, and a multi-factorial management is needed to prevent or delay complications [3].”
BackgroundYoung, K., McInnes, E. H., Massey, R. J., Kahkoska, A. R., Pilla, S. J., Raghavan, S., Stanislawski, M. A., Tobias, D. K., McGovern, A. P., Dawed, A. Y., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00359-w · Cited by 55
“In addition, these drugs are recommended as second-line glucose lowering medications to be added after metformin 6 .”
Waibel, F. W. A., Uçkay, İ., Soldevila‐Boixader, L., Sydler, C., & Gariani, K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1323315 · Cited by 72
“The choice of anti-diabetic treatment must be individualized according to several parameters such as glycemic and weight goals, cardio-renal protection, side effects associated with treatments, mode of administration or even cost or accessibility (13).”
BackgroundGuan, H., Tian, J., Wang, Y., Niu, P., Zhang, Y., Zhang, Y., Fang, X., Miao, R., Yin, R., & Tong, X. (2024) · European journal of medical research · doi:10.1186/s40001-024-01739-1 · Cited by 63
“Recently, both the American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update their consensus statement on adult T2DM management, emphasizing the importance of weight management within the overall approach to diabetes care [129].”
BackgroundTirzepatide for overweight and obesity management
Hamza, M., Papamargaritis, D., & Davies, M. J. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2436595 · Cited by 43
“…treatment choice for individuals with obesity and T2D (without established cardiovascular or kidney disease) and the updated international guidelines for management of hyperglycemia in T2D have endorsed tirzepatide as a highly effective treatment for achieving both glycemic con-trol and WL [85].”
Self-citationDwibedi, C., Ekström, O., Brandt, J., Adiels, M., Franzén, S., Abrahamsson, B., & Rosengren, A. H. (2024) · Nature Metabolism · doi:10.1038/s42255-023-00943-3 · Cited by 40
“This is relevant because current guidelines emphasize the potential value of intensifying treatment even in patients with lower glycaemic levels 1,17 .”
InfluentialPharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events
He, L., Li, Q., Yang, Y., Li, J., Luo, W., Huang, Y., & Zhong, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1416985 · Cited by 40
Internet of Things enabled open source assisted real-time blood glucose monitoring framework
Abubeker, K. M., Ramani., R., Krishnamoorthy, R., Gogula, S., Baskar, S., Muthu, S., Chellamuthu, G., & Subramaniam, K. (2024) · Scientific Reports · doi:10.1038/s41598-024-56677-z · Cited by 52
Lingvay, I., Bergenheim, S. J., Buse, J. B., Freitas, P., Garvey, W. T., Harder-Lauridsen, N. M., Rosenstock, J., Sahu, K., & Wharton, S. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00225-6 · Cited by 63
Self-citation3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s003 · Cited by 106
Self-citationLim, C.-E., Pasternak, B., Eliasson, B., Danaei, G., & Ueda, P. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac315 · Cited by 45
The AMD ANNALS: A continuous initiative for the improvement of type 2 diabetes care
Russo, G., Di Bartolo, P., Candido, R., Lucisano, G., Manicardi, V., Giandalia, A., Nicolucci, A., Rocca, A., Rossi, M. C., & Di Cianni, G. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110672 · Cited by 39
Metformin beyond type 2 diabetes: Emerging and potential new indications
Petrie, J. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15756 · Cited by 61
Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity
Eržen, S., Tonin, G., Jurišić‐Eržen, D., & Klen, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031517 · Cited by 49
“It might be used in patients with insufficient glycemic control who have already received basal insulin therapy and require additional short-acting agents but aim to avoid weight gain [61].”
BackgroundSecondary diabetes mellitus in acromegaly
Moustaki, M., Paschou, S. Α., Xekouki, P., Kotsa, K., Peppa, Μ., Ψαλτοπούλου, Θ., Kalantaridou, S., & Vryonidou, A. (2023) · Endocrine · doi:10.1007/s12020-023-03339-1 · Cited by 45
Short-chain fatty acids as a link between diet and cardiometabolic risk: a narrative review
Birkeland, E., Gharagozlian, S., Valeur, J., & Aas, A. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01803-5 · Cited by 52
“Introduction The role of diet in health and chronic conditions such as obesity, insulin resistance, and cardiovascular disease is well known [1] and recognized in clinical guidelines [2, 3].”
BackgroundEfficacy of Fasting in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review
Herz, D., Haupt, S., Zimmer, R. T., Wachsmuth, N. B., Schierbauer, J., Zimmermann, P., Voit, T., Thurm, U., Khoramipour, K., RILSTONE, S. K., et al. (2023) · Nutrients · doi:10.3390/nu15163525 · Cited by 49
“prevalence of obesity, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have assembled a panel to update consensus statements on the treatment of T2DM [4].”
BackgroundInfluentialAnyiam, O., Phillips, B., Quinn, K., Wilkinson, D., Smith, K., Atherton, P., & Idris, I. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.06.034 · Cited by 40
Trends and risk factors of diabetes and prediabetes in US adolescents, 1999–2020
Ouyang, A., Hu, K., & Chen, L. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111022 · Cited by 45
Cardoso, P., Young, K., Nair, A. T. N., Hopkins, R., McGovern, A. P., Haider, E., Karunaratne, P., Donnelly, L. A., Mateen, B. A., Sattar, N. A., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06099-3 · Cited by 42
Lingvay, I., Cheng, A. Y., Levine, J. A., Gomez‐Valderas, E., Allen, S. E., Ranta, K., Torcello‐Gómez, A., & Thieu, V. T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14943 · Cited by 36
“0% while controlling weight and avoiding hypoglycaemia.(2) The findings in SURPASS-2 compare favourably with the proportions of participants achieving the composite endpoint of HbA1c less than 7.”
BackgroundResultDunn, T. C., Xu, Y., Bergenstal, R. M., Ogawa, W., & Ajjan, R. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0146 · Cited by 47
“12,13 Importantly, failure to consider this discordance may lead to clinical risks if treatment decisions are based solely on HbA1c values.”
Feng, J., Zhang, Q., Chen, B., Chen, J., Wang, W., Hu, Y., Yu, J., & Huang, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1360998 · Cited by 48
Zhao, T., Yang, Q., Feuerbacher, J. F., Yu, B., Brinkmann, C. K., Cheng, S., Bloch, W., & Schumann, M. (2024) · British Journal of Sports Medicine · doi:10.1136/bjsports-2024-108127 · Cited by 45
“The main characteristics of the included studies and participants are summarised in online supplemental appendix 7.”
Munshi, M. N., Kahkoska, A. R., Neumiller, J. J., Alexopoulos, A., Allen, N. A., Cukierman‐Yaffe, T., Huang, E. S., Lee, S. J., Lipska, K. J., McCarthy, L. M., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00372-3 · Cited by 49
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy
Rosenstock, J., Bailey, T. S., Connery, L. E., Miller, E. M., Desouza, C. V., Wang, Q., Leohr, J. K., Knights, A., Carr, M. C., & Child, C. J. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502796 · Cited by 37
Rosenstock, J., Yabe, D., Cox, D., Li, J., Denning, M., Wu, W.-S., Liu, R., Zhao, Y., Manghi, F. P., Abalos, F., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00202-3 · Cited by 50
The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis
Stachteas, P., Karakasis, P., Patoulias, D., Clemenza, F., Fragakis, N., & Rizzo, M. (2023) · Annals of Medicine · doi:10.1080/07853890.2024.2304667 · Cited by 36
The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure
Stachteas, P., Nasoufidou, A., Patoulias, D., Karakasis, P., Karagiannidis, E., Mourtzos, M.-A., Samaras, A., Apostolidou, X., & Fragakis, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063122 · Cited by 35
Mousavi, A., Shojaei, S., Soleimani, H., Semirani-Nezhad, D., Ebrahimi, P., Zafari, A., Ebrahimi, R., Roozbehi, K., Harrison, A., Syed, M., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01635-6 · Cited by 44
“The European Association for the Study of Diabetes (EASD 2022) also recommends SGLT-2is and GLP-1RA independent of metformin use in patients with high-risk of ASCVD, heart failure, and CKD [15].”
Anyiam, O., Ardavani, A., Rashid, R. S. A., Panesar, A., & IDRIS, I. R. (2025) · Obesity Reviews · doi:10.1111/obr.13916 · Cited by 49
“13 More recently, the powerful weight-reducing effects of GLP1RAs have been exploited for use in the management of obesity.”
Webster, C. C., Murphy, T., Larmuth, K., Noakes, T. D., & Smith, J. A. H. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s227090 · Cited by 41
Vasdeki, D., Koufakis, T., Tsamos, G., Busetto, L., Zebekakis, P. E., & Kotsa, K. (2022) · Nutrients · doi:10.3390/nu14224801 · Cited by 33
Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update
Giglio, R. V., Patti, A. M., Rizvi, A. A., Stoian, A. P., Ciaccio, M., Παπάνας, Ν., Janež, A., Sönmez, A., Banach, M., Sahebkar, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020291 · Cited by 41
Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin
Chan, J. C. N., Yang, A., Chu, N. H. S., & Chow, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15700 · Cited by 38
“32 With respect to glucose lowering, the ADA/EASD 2022 consensus recommended that the choice of GLDs should be personalized based on considerations of efficacy, side effects (notably weight gain and hypoglycaemia) and costs.”
Insulin resistance, bone health, and fracture risk
Armutçu, F., & McCloskey, E. V. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07227-w · Cited by 38
McLean, P., Bennett, J., Woods, E. A., Chandrasekhar, S. A., Newman, N. A., Mohammad, Y., Khawaja, M., Rizwan, A. M., Siddiqui, R., Birnbaum, Y., et al. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00068-z · Cited by 49
Type 2 Diabetes and the Multifaceted Gut-X Axes
Guo, H., Pan, L.-T., Wu, Q., Wang, L., Huang, Z., Wang, J., Wang, L., Fang, X., Dong, S., Zhu, Y., et al. (2025) · Nutrients · doi:10.3390/nu17162708 · Cited by 44
Metabolic syndrome and heart failure: mechanism and management
Laksono, S., & Prawara, A. S. (2021) · Medicine and Pharmacy Reports · doi:10.15386/mpr-1884 · Cited by 35
Fujii, M., Ohno, Y., Ikeda, A., Godai, K., Li, Y., Nakamura, Y., Yabe, D., Tsushita, K., Kashihara, N., Kamide, K., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01185-2 · Cited by 42
Napoli, R., Berra, C., Catarig, A., Di Loreto, C., Donatiello, E., Berentzen, T. L., Pitocco, D., & Giorgino, F. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15020 · Cited by 32
“Yet, few patients in Italy are treated with SGLT2is or GLP-1RAs, in contrast with current national and international guidelines.(2,3,6,7) However, the study presented herein was based on the then current 2018 Italian guidelines,(10) which recommended GLP-1RAs as second-line therapy after metformin, regardless of patie…”
ResultDening, J., Mohebbi, M., Abbott, G., George, E. S., Ball, K., & Islam, S. M. S. (2023) · Nutrition & Diabetes · doi:10.1038/s41387-023-00240-8 · Cited by 31
“Importantly, LCDs are supported by international diabetes guidelines as a suitable dietary choice for people with T2DM [2, 15 – 19].”
BackgroundGourdy, P., Schiele, F., Halimi, J., Kownator, S., Hadjadj, S., & Valensi, P. E. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1227769 · Cited by 36
“According to the latest guidelines by the ADA, the EASD, and the ESC (2, 11, 48), SGLT2is should be prioritized in patients with T2DM and established HF, particularly those with a reduced ejection fraction (HFrEF), to reduce the risk of worsening HF and cardiovascular death.”
BackgroundMethodInfluentialBi, J., Zheng, M., Li, K., Sun, S., Zhang, Z., Yan, N., & Li, X. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02205-2 · Cited by 35
“With the rapid urbanization and modernization in China, type 2 diabetes mellitus (T2DM) has become an important health issue and chronic non-communicable disease with the highest morbidity and mortality rates, imposing heavy burden on individuals and society [1].”
BackgroundGogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2356254 · Cited by 32
“On the other hand, for many people with overweight/obesity and T2D, a weight-centric approach has recently been proposed in the ADA/EASD 2022 guidelines [9].”
BackgroundInfluentialSelf-citationAmin, N. B., Frederich, R. C., Tsamandouras, N., Haggag, A. Z., Schuster, T., Żmuda, W., Palmer, A., Vasas, S., Buckley, G., Smith, T. R., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16005 · Cited by 39
Yin, M., Li, Y., Aziz, A. R., Buffey, A., Bishop, D. J., Bao, D., Nassis, G. P., Islam, H., Wang, H., Fyfe, J. J., et al. (2026) · Journal of Sport and Health Science · doi:10.1016/j.jshs.2025.101088 · Cited by 35
“226”
Patti, A. M., Giglio, R. V., Allotta, A., Bruno, A., Bella, T. D., Stoian, A. P., Ciaccio, M., & Rizzo, M. (2023) · Biomedicines · doi:10.3390/biomedicines11051362 · Cited by 36
Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review
Panico, C., Bonora, B. M., Camera, A., Chilelli, N. C., Prato, G. D., Favacchio, G., Grancini, V., Resi, V., Rondinelli, M., Zarra, E., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01855-y · Cited by 39
“As a result, treatment approaches are changing rapidly with preference now given to agents whose benefits extend beyond glucose-lowering [2].”
BackgroundDing, Y., Shi, Y., Guan, R., Yan, S., Liu, H., Wang, Z., Li, J., Wang, T., Cai, W., & Ma, G. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2023.107031 · Cited by 31
Machine learning-based reproducible prediction of type 2 diabetes subtypes
Tanabe, H., Sato, M., Miyake, A., Shimajiri, Y., Ojima, T., Narita, A., Saito, H., Tanaka, K., Masuzaki, H., Kazama, J. J., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06248-8 · Cited by 48
“When choosing a glucose-lowering drug, the decision has recently shifted from being based on side effects and cost-effectiveness to being based on evidence for the prevention of diabetes complications, such as CVD, heart failure and chronic kidney disease (CKD) [3, 4].”
Yang, R., Zhang, L., Guo, J., Wang, N., Zhang, Q., Qi, Z., Wu, L., Qin, L., & Liu, T. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06302-y · Cited by 39
Gastaldi, G., Lucchini, B., Thalmann, S., Alder, S., Laimer, M. W., Brändle, M., Wiesli, P., Lehmann, R., & Working group of the SGED/SSED (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40060 · Cited by 38
Vernstrøm, L., Gullaksen, S., Sørensen, S. S., Funck, K. L., Laugesen, E., & Poulsen, P. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15464 · Cited by 30
Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population
Buckley, A., Suliman, S., Allum, M., Mohammed, N., Lessan, N., le Roux, C. W., & Suliman, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15680 · Cited by 29
Wang, H., Cordiner, R. L. M., Huang, Y., Donnelly, L. A., Hapca, S. M., Collier, A., McKnight, J. A., Kennon, B., Gibb, F. W., McKeigue, P., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1238 · Cited by 35
“Although other clinical factors such as hypoglycemia risk and durability regarding SU need to be considered (39), our findings from this study support the most recent international guidelines (40), which recommend SU as one of the second-line options after metformin if resources are limited.”
ResultCorbin, L. J., Hughes, D. A., Bull, C. J., Vincent, E. E., Smith, M. L., McConnachie, A., Messow, C., Welsh, P. I., Taylor, R., Lean, M. E. J., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-06019-x · Cited by 34
“This suggests that weight change is upstream of many disease-associated metabolite alterations, in line with growing consensus of the importance of excess adiposity in the pathogenesis of diabetes and, as a treatment target, as reflected in recent ADA/EASD recommendations [41].”
Socioeconomic factors associated with poor medication adherence in patients with type 2 diabetes
Ekenberg, M., Qvarnström, M., Sundström, A., Martinell, M., & Wettermark, B. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03571-8 · Cited by 46
Modifiable Cardiometabolic Risk Factors in Survivors of Childhood Cancer
Hammoud, R. A., Mulrooney, D. A., Rhea, I. B., Yu, C. H., Johnson, J. N., Chow, E. J., Ehrhardt, M. J., Hudson, M. M., Ness, K. K., Armstrong, G. T., et al. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.12.008 · Cited by 35
Therapeutic advancements in nanomedicine: The multifaceted roles of silver nanoparticles
Karunakar, K. K., Cheriyan, B. V., Krithikeshvaran, R., Gnanisha, M., & Abinavi, B. (2024) · Biotechnology Notes · doi:10.1016/j.biotno.2024.05.002 · Cited by 37
Lan, N. S. R., Dwivedi, G., Fegan, P. G., Game, F. L., & Hamilton, E. J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02527-1 · Cited by 42
Lingvay, I., Benamar, M., Chen, L., Fu, A., Jódar, E., Nishida, T., Riveline, J., Yabe, D., Züger, T., & Rea, R. R. (2025) · Diabetologia · doi:10.1007/s00125-024-06348-5 · Cited by 40
“When diabetes progresses to the point that several non-insulin glucose-lowering medications are no longer effective in providing individuals with adequate glucose management, the initiation of insulin is recommended [1, 2].”
Davies, M. J., van der Meer, P., Verma, S., Patel, S., Chinnakondepalli, K. M., Borlaug, B. A., Butler, J., Kitzman, D. W., Shah, S. J., Harring, S., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00304-8 · Cited by 32
Self-citationBhargava, A., Bergenstal, R. M., Warren, M., Thrasher, J. R., Dempsey, M. A., Bode, B. W., LaRocque, J., Carlson, A. L., Keiter, A., Ma, H., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0586 · Cited by 34
Rroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 35
Battelino, T., Lalic, N. M., Hussain, S., Ceriello, A., Majanović, S. K., Davies, S., Topsever, P., Heverly, J., Ulivi, F., Brady, K., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112111 · Cited by 36
Self-citationKristensen, F. P. B., Sanchez-Lastra, M. A., Dalene, K. E., del Pozo Cruz, B., Ried-Larsen, M., Thomsen, R. W., Ding, D., Ekelund, U., & Tarp, J. (2023) · Diabetes Care · doi:10.2337/dc23-0937 · Cited by 29
Raiten, J. M., Morlok, A. P., D'Ambrosia, S., Ruggero, M. A., & Flood, J. (2023) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2023.10.011 · Cited by 36
Firman, C., Mellor, D. D., Unwin, D., & Brown, A. C. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01492-4 · Cited by 33
“…glycaemia within target range of a glycated haemoglobin (HbA1c) of less than 7% (53 mmol/mol) [4] as recommended by clinical guidelines or even to support the achievement of drug-free remission [5, 6], and in doing so reduce the risk of diabetes associated micro-and macrovascular complications [7].”
Neuen, B. L., Jun, M., Wick, J., Kotwal, S. S., Badve, S. V., Jardine, M., Gallagher, M., Chalmers, J. P., Nallaiah, K., Perkovic, V., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100988 · Cited by 34
Green, J. B., Everett, B. M., Ghosh, A., Younes, N., Krause-Steinrauf, H. J., Barzilay, J. I., Desouza, C. V., Inzucchi, S. E., Pokharel, Y., Schade, D. S., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.066604 · Cited by 30
“28,31 Although these differences reflect the lack of outcomes data in lower-risk populations, such dichotomy in guidelines may not be justifiable, given that, over a lifespan, diabetes will confer substantial cardiovascular risk.”
BackgroundSelf-citationAssociation of a Low-Carbohydrate High-Fat Diet With Plasma Lipid Levels and Cardiovascular Risk
Iatan, I., Huang, K., Vikulova, D. N., Ranjan, S., & Brunham, L. R. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.100924 · Cited by 33
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 33
A Comprehensive Analysis of Diabetic Complications and Advances in Management Strategies
IWASAKI, H. O., Yagyu, H., & Shimano, H. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65551 · Cited by 52
“Diabetic patients have a two-to four-fold increased risk of CVD compared to non-diabetic individuals, primarily due to insulin resistance, dyslipidemia, chronic inflammation, and endothelial dysfunction 25, 26) .”
Dwibedi, C. K., Axelsson, A. S., Abrahamsson, B., Fahey, J. W., Asplund, O., Hansson, O., Ahlqvist, E., Tremaroli, V., Bäckhed, F., & Rosengren, A. H. (2025) · Nature Microbiology · doi:10.1038/s41564-025-01932-w · Cited by 41
“…Health Organization criteria rather than the wider criteria proposed by the American Diabetes Association, as it enabled the investigation of individuals with more severe disease progression and higher risk for adverse outcomes, who are likely to benefit more from therapeutic interventions 8 .”
InfluentialDavies, M. J., Lim, S. K., Slater, T., Goldney, J., Philis‐Tsimikas, A., Franco, D. R., Lamptey, R., Yates, T. E., Tankova, T. I., & Lingvay, I. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00687-w · Cited by 63
Self-citationGomez-Peralta, F., & Abreu, C. (2019) · Drug Design, Development and Therapy · doi:10.2147/dddt.s165372 · Cited by 27
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
Xiong, S., Gou, R., Liang, X., Wu, H., Qin, S., Li, B., Luo, C., & Chen, J. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01594-7 · Cited by 26
Bozkurt, B., Rossignol, P., & Vassalotti, J. A. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3683 · Cited by 34
Kuhre, R. E., Ballarín-González, B., Brand, C. L., Glendorf, T., Madsen, K. G., Hjøllund, K. R., Hogendorf, W. F. J., Ipsen, D. H., Lundh, S. H., Kruse, T., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105862 · Cited by 29
The Inflammatory Bridge Between Type 2 Diabetes and Neurodegeneration: A Molecular Perspective
Kacem, H., d’Angelo, M., Qosja, E., Topi, S., Castelli, V., & Cimini, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157566 · Cited by 41
“Treatments to usual care focus on improving glycemic control and insulin sensitivity by lifestyle intervention and pharmacologic interventions, including metformin (which augments AMP-activated protein kinase activity), GLP-1 receptor agonists, SGLT2 inhibitors, and insulin therapy [27].”
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 45
Sugiyama, S., Jinnouchi, H., Yoshida, A., Hieshima, K., Kurinami, N., Jinnouchi, K., Tanaka, M., Suzuki, T., MIYAMOTO, F., Kajiwara, K., et al. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3761 · Cited by 31
Korayem, G. B., Alshaya, O. A., Alghamdi, A. A., ALANAZI, S., Almutib, R. T., Alsaileek, M., Alrashidi, A., Aldosari, N., Sheraim, N. B., Yami, M. S. A., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1031306 · Cited by 26
“Moreover, patients with established HF or CKD were 3.2% and 7.7%, respectively, in the preferably prescribed group.”
BackgroundInfluentialSahay, R. K., Giri, R., Shembalkar, J., Gupta, S. K., Mohan, B., Kurmi, P. H., Kumar, S., Sawardekar, V. M., Mishra, A., Murthy, L. S., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02523-z · Cited by 30
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.